- Home
- FBRX vs INFU Comparison
FBRX vs INFU Comparison
Compare FBRX & INFU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBRX
- INFU
- Stock Information
- Founded
- FBRX N/A
- INFU 2005
- Country
- FBRX United States
- INFU United States
- Employees
- FBRX N/A
- INFU N/A
- Industry
- FBRX Biotechnology: Pharmaceutical Preparations
- INFU Medical/Dental Instruments
- Sector
- FBRX Health Care
- INFU Health Care
- Exchange
- FBRX Nasdaq
- INFU Nasdaq
- Market Cap
- FBRX 154.5M
- INFU 180.4M
- IPO Year
- FBRX N/A
- INFU N/A
- Fundamental
- Price
- FBRX $11.57
- INFU $9.63
- Analyst Decision
- FBRX Strong Buy
- INFU Strong Buy
- Analyst Count
- FBRX 2
- INFU 1
- Target Price
- FBRX $61.00
- INFU $12.00
- AVG Volume (30 Days)
- FBRX 53.8K
- INFU 245.8K
- Earning Date
- FBRX 08-14-2025
- INFU 08-05-2025
- Dividend Yield
- FBRX N/A
- INFU N/A
- EPS Growth
- FBRX N/A
- INFU 2168.02
- EPS
- FBRX N/A
- INFU 0.24
- Revenue
- FBRX N/A
- INFU $139,886,000.00
- Revenue This Year
- FBRX N/A
- INFU $11.06
- Revenue Next Year
- FBRX N/A
- INFU $7.86
- P/E Ratio
- FBRX N/A
- INFU $40.58
- Revenue Growth
- FBRX N/A
- INFU 8.13
- 52 Week Low
- FBRX $4.11
- INFU $4.61
- 52 Week High
- FBRX $28.68
- INFU $9.97
- Technical
- Relative Strength Index (RSI)
- FBRX 57.91
- INFU 82.64
- Support Level
- FBRX $9.91
- INFU $8.44
- Resistance Level
- FBRX $11.26
- INFU $9.93
- Average True Range (ATR)
- FBRX 0.84
- INFU 0.60
- MACD
- FBRX 0.15
- INFU 0.37
- Stochastic Oscillator
- FBRX 88.53
- INFU 93.33
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).
About INFU InfuSystems Holdings Inc.
InfuSystems Holdings Inc is a health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. INFU services are provided under a two-reportable segment. The first is Patient Services, providing the last-mile solution for clinic-to-home healthcare where the continuing treatment involves complex durable medical equipment and services. The Patient segment is comprised of Oncology, Pain Management and Wound Therapy businesses. The second, Device Solutions, supports the Patient Services platform and leverages service orientation to win incremental business from its direct payer clients. The Device segment is comprised of direct payer rentals, pump and consumable sales, and biomedical services and repair. Majority from Patient.